← All drugs
Drug · FAERS side-effect profile with label screen

Hydromorphone side effects: what 91,449 FDA adverse event reports show

Hydromorphone Hydrochloride · 1,225 reaction terms · 421,036 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Label matched

Hydromorphone Hydrochloride (Hydromorphone Hydrochloride)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

91,449 reports · 93% serious · 28,105 with death outcome · 52% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone hydrochloride ora.

FDA label, Indications and Usage

What it is

Hydromorphone is a morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.

PubChem CID 5284570 (ChEBI)

Boxed warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE See full prescribing information for complete boxed warning . Ensure accuracy when prescribing, dispensing, and administering hydromorphone hydrochloride oral solution.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Labeled (related wording) 6Reporting / coding artifact 7Lab value / disease marker 1Not in label — unassessed 25
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,185 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Vaginal flatulence224646.9
500.0–837.0ROR 648.5 · calibrated p 9e-15 ✓
165.5 EB05 148.1 · IC025 +6.7
3/3 methods agree
Not in label — unassessedserious n=224 · ♀ 100% (drug 52%)no trial arm names this drug
Antacid therapy69310.9
216.0–447.3ROR 311.1 · calibrated p 3e-11 ✓
126.7 EB05 103.5 · IC025 +5.7
3/3 methods agree
Reporting / coding artifactserious n=69 · ♀ 0% (drug 52%) · 100% clinicianno trial arm names this drug
Sleep disorder therapy98256.7
192.2–342.9ROR 257.0 · calibrated p 1e-10 ✓
117.8 EB05 99.5 · IC025 +5.9
3/3 methods agree
Reporting / coding artifactserious n=98 · ♀ 0% (drug 52%) · 100% clinicianno trial arm names this drug
Appendicolith166178.9
145.9–219.3ROR 179.2 · calibrated p 1e-9 ✓
99.0 EB05 87.0 · IC025 +6.0
3/3 methods agree
Not in label — unassessedserious n=166 · ♀ 0% (drug 52%) · 100% clinicianno trial arm names this drug
Inspiratory capacity decreased95120.9
94.2–155.1ROR 121.0 · calibrated p 4e-8 ✓
77.8 EB05 65.6 · IC025 +5.5
3/3 methods agree
Not in label — unassessedserious n=95 · ♀ 0% (drug 52%) · 100% clinicianno trial arm names this drug
Analgesic therapy102114.3
90.1–145.1ROR 114.4 · calibrated p 6e-8 ✓
75.1 EB05 63.7 · IC025 +5.5
3/3 methods agree
Reporting / coding artifactserious n=102 · ♀ 0% (drug 52%) · 100% clinicianno trial arm names this drug
Drug therapy102107.4
84.8–135.9ROR 107.5 · calibrated p 1e-7 ✓
72.1 EB05 61.1 · IC025 +5.4
3/3 methods agree
Reporting / coding artifactserious n=102 · ♀ 0% (drug 52%) · 100% clinicianno trial arm names this drug
Learning disability1,55192.6
87.3–98.2ROR 94.2 · calibrated p 2e-7 ✓
65.9 EB05 63.1 · IC025 +5.9
3/3 methods agree
Not in label — unassessedserious n=1,548 · 100% consumerno trial arm names this drug
Neonatal hypoacusis6384.0
62.9–112.1ROR 84.0 · calibrated p 7e-7 ✓
60.4 EB05 48.9 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=63 · 100% consumerno trial arm names this drug
Anticoagulant therapy6772.9
55.4–96.0ROR 73.0 · calibrated p 2e-6 ✓
54.5 EB05 44.4 · IC025 +4.9
3/3 methods agree
Reporting / coding artifactserious n=67 · ♀ 0% (drug 52%) · 100% clinicianno trial arm names this drug
Congenital hiatus hernia5270.1
51.4–95.7ROR 70.2 · calibrated p 2e-6 ✓
52.7 EB05 41.8 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=52 · ♀ 0% (drug 52%) · 100% clinicianno trial arm names this drug
Malignant melanoma stage 04166.9
47.2–94.8ROR 67.0 · calibrated p 4e-6 ✓
50.7 EB05 38.9 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=41 · ♀ 0% (drug 52%) · 100% clinicianno trial arm names this drug
Drug dependence35,11263.1
62.4–63.7ROR 101.7 · calibrated p 1e-7 ✓
49.5 EB05 49.1 · IC025 +5.6
3/3 methods agree
Reporting / coding artifactage-adj. PRR 30.3 · serious PRR 31.4 · 96% consumerno trial arm names this drug
Temperature regulation disorder33441.3
36.7–46.4ROR 41.4 · calibrated p 4e-5 ✓
35.0 EB05 31.9 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=333 · ♀ 100% (drug 52%)no trial arm names this drug
Developmental delay1,38841.2
38.9–43.6ROR 41.8 · calibrated p 4e-5 ✓
35.0 EB05 33.4 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious PRR 22.0 · 100% consumerno trial arm names this drug
Emotional distress17,70539.0
38.5–39.6ROR 48.2 · calibrated p 2e-5 ✓
33.4 EB05 33.0 · IC025 +5.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 5.5 · serious PRR 22.9 · 91% consumerno trial arm names this drug
Female genital tract fistula24237.4
32.7–42.9ROR 37.5 · calibrated p 8e-5 ✓
32.2 EB05 28.9 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=242 · ♀ 100% (drug 52%)no trial arm names this drug
Amaurosis fugax14335.3
29.6–42.1ROR 35.3 · calibrated p 1e-4 ✓
30.5 EB05 26.6 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=143 · 100% clinicianno trial arm names this drug
Self esteem decreased30933.2
29.4–37.4ROR 33.3 · calibrated p 2e-4 ✓
29.0 EB05 26.4 · IC025 +4.6
3/3 methods agree
Not in label — unassessedserious n=309 · 100% consumerno trial arm names this drug
Retinitis20331.6
27.3–36.6ROR 31.7 · calibrated p 2e-4 ✓
27.8 EB05 24.7 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=203 · ♀ 100% (drug 52%) · 100% clinicianno trial arm names this drug
Soft tissue disorder12428.5
23.6–34.4ROR 28.5 · calibrated p 4e-4 ✓
25.3 EB05 21.8 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=123 · ♀ 100% (drug 52%)no trial arm names this drug
Overdose23,06027.2
26.9–27.6ROR 36.1 · calibrated p 9e-5 ✓
24.4 EB05 24.1 · IC025 +4.6
3/3 methods agree
Reporting / coding artifactage-adj. PRR 7.4 · serious PRR 19.1 · 89% consumerno trial arm names this drug
Radiculopathy26525.5
22.5–29.0ROR 25.6 · calibrated p 6e-4 ✓
23.0 EB05 20.8 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=263 · ♀ 94% (drug 52%)no trial arm names this drug
Lupus vulgaris11023.3
19.1–28.3ROR 23.3 · calibrated p 0.001 ✓
21.1 EB05 18.0 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=110 · ♀ 100% (drug 52%) · 100% clinicianno trial arm names this drug
Nasal oedema15922.2
18.9–26.2ROR 22.3 · calibrated p 0.001 ✓
20.3 EB05 17.8 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=159 · ♀ 100% (drug 52%) · 100% clinicianno trial arm names this drug
Proctitis23520.9
18.3–23.9ROR 21.0 · calibrated p 0.002 ✓
19.2 EB05 17.2 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=235 · ♀ 100% (drug 52%)no trial arm names this drug
Hypermobility syndrome4120.6
15.0–28.4ROR 20.6 · calibrated p 0.002 ✓
18.8 EB05 14.4 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=41 · ♀ 100% (drug 52%) · 100% clinicianno trial arm names this drug
Substance use disorder24719.9
17.5–22.7ROR 20.0 · calibrated p 0.002 ✓
18.4 EB05 16.5 · IC025 +3.9
3/3 methods agree
Labeled adverse reaction
exact term
serious n=247 · 100% consumerno trial arm names this drug
Imprisonment14019.4
16.3–23.0ROR 19.4 · calibrated p 0.002 ✓
17.9 EB05 15.5 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=140 · ♀ 31% (drug 52%) · 100% consumerno trial arm names this drug
Implant site extravasation6119.1
14.7–24.8ROR 19.1 · calibrated p 0.003 ✓
17.6 EB05 14.1 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=50no trial arm names this drug
Chronic sinusitis26717.5
15.5–19.9ROR 17.6 · calibrated p 0.004 ✓
16.3 EB05 14.7 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=267 · ♀ 100% (drug 52%)no trial arm names this drug
Bone erosion25117.4
15.3–19.8ROR 17.5 · calibrated p 0.004 ✓
16.2 EB05 14.6 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=251 · ♀ 100% (drug 52%) · 93% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody4717.3
12.9–23.3ROR 17.3 · calibrated p 0.005 ✓
16.0 EB05 12.4 · IC025 +3.3
3/3 methods agree
Lab value / disease markerserious n=47 · ♀ 100% (drug 52%) · 100% clinicianno trial arm names this drug
Spina bifida14116.4
13.8–19.5ROR 16.4 · calibrated p 0.005 ✓
15.3 EB05 13.3 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=141 · 100% consumerno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Dependence / withdrawal36,62532.332.0–32.6signal
Depression3,0332.52.4–2.6signal
Serious infection4,8441.41.4–1.5raised
Hyponatraemia5021.41.3–1.6raised
Suicidality1,4701.41.3–1.4raised
Venous thromboembolism1,2871.41.3–1.4raised
Liver injury1,7391.31.3–1.4raised
Anaemia1,6181.21.2–1.3raised
Fall / fracture1,9201.21.1–1.2raised
Pancreatitis4041.11.0–1.3raised
Gi bleeding9151.11.1–1.2raised
Thrombocytopenia1,0081.01.0–1.1no difference
Opportunistic infection5941.00.9–1.1no difference
Tendon disorder1530.90.8–1.1no difference
Seizure7330.90.8–0.9lower than other drugs
Anaphylaxis / angioedema4610.80.8–0.9lower than other drugs

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Hydromorphone only as a background or rescue medication (NCT02625181, NCT03472469); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug dependence35,11263.1
62.4–63.7ROR 101.7 · calibrated p 1e-7 ✓
49.5 EB05 49.1 · IC025 +5.6
3/3 methods agree
Reporting / coding artifactage-adj. PRR 30.3 · serious PRR 31.4 · 96% consumerno trial arm names this drug
Overdose23,06027.2
26.9–27.6ROR 36.1 · calibrated p 9e-5 ✓
24.4 EB05 24.1 · IC025 +4.6
3/3 methods agree
Reporting / coding artifactage-adj. PRR 7.4 · serious PRR 19.1 · 89% consumerno trial arm names this drug
Pain22,2868.6
8.5–8.7ROR 11.0 · calibrated p 0.023 ✓
8.3 EB05 8.2 · IC025 +3.0
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 5.2 · serious PRR 7.9no trial arm names this drug
Emotional distress17,70539.0
38.5–39.6ROR 48.2 · calibrated p 2e-5 ✓
33.4 EB05 33.0 · IC025 +5.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 5.5 · serious PRR 22.9 · 91% consumerno trial arm names this drug
Death14,9114.0
4.0–4.1ROR 4.6 · calibrated p 0.281
4.0 EB05 3.9 · IC025 +2.0
3/3 methods agree
Outcome field, not a reaction
boxed warning mentions mortality
age-adj. PRR 1.5 · serious PRR 2.5 · 79% consumerno trial arm names this drug
Toxicity to various agents10,08114.6
14.3–14.9ROR 16.3 · calibrated p 0.005 ✓
13.8 EB05 13.5 · IC025 +3.7
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.1 · serious PRR 8.8no trial arm names this drug
Nausea4,7581.4
1.3–1.4ROR 1.4 · calibrated p 0.579
1.4 EB05 1.4 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 3.1 · serious PRR 1.4no trial arm names this drug
Drug ineffective (drug did not work)4,4740.8
0.8–0.8ROR 0.8 · calibrated p 0.165
0.8 EB05 0.8 · IC025 -0.4
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 2.2 · serious PRR 1.2 · ♀ 74% (drug 52%)no trial arm names this drug
Fatigue (tiredness)3,6171.1
1.0–1.1ROR 1.1 · calibrated p 0.353
1.1 EB05 1.0 · IC025 +0.0Labeled adverse reaction
exact term
age-adj. PRR 2.6 · serious PRR 1.1no trial arm names this drug
Vomiting3,5301.7
1.7–1.8ROR 1.8 · calibrated p 0.807
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 3.9 · serious PRR 1.5 · ♀ 73% (drug 52%)no trial arm names this drug
Off label use (used outside approved label)3,4140.9
0.9–0.9ROR 0.9 · calibrated p 0.242
0.9 EB05 0.9 · IC025 -0.2
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 2.2 · serious PRR 1.0no trial arm names this drug
Anxiety3,3852.7
2.7–2.8ROR 2.8 · calibrated p 0.692
2.7 EB05 2.6 · IC025 +1.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 3.2 · serious PRR 2.2no trial arm names this drug
Drug abuse3,1208.8
8.5–9.2ROR 9.1 · calibrated p 0.044 ✓
8.5 EB05 8.3 · IC025 +3.0
3/3 methods agree
Reporting / coding artifactage-adj. PRR 4.2 · serious PRR 5.4 · 85% consumerno trial arm names this drug
Headache3,0221.1
1.1–1.1ROR 1.1 · calibrated p 0.380
1.1 EB05 1.1 · IC025 +0.1Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 1.3 · ♀ 81% (drug 52%)no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Hydromorphone ↔ Drug dependence.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Hydromorphone?

In FDA FAERS, the most frequently co-reported reaction terms for Hydromorphone are pain, emotional distress, drug withdrawal syndrome, toxicity to various agents, nausea, fatigue. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Hydromorphone have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE See full prescribing information for complete boxed warning . Ensure accuracy when prescribing, dispensing, and administering hydromorphone hydrochloride oral solution.

Do FAERS signals prove that Hydromorphone causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.